Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aldeyra Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALDX
Nasdaq
2834
www.aldeyra.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aldeyra Therapeutics, Inc.
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
- Oct 5th, 2026 8:46 am
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
- Oct 5th, 2026 8:36 am
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
- Oct 1st, 2026 7:42 am
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
- Sep 29th, 2026 9:02 am
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
- Sep 29th, 2026 8:49 am
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
- Sep 29th, 2026 8:12 am
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
- Sep 29th, 2026 7:06 am
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
- Sep 29th, 2026 5:00 am
Aldeyra Therapeutics to Host Regulatory Update Webcast
- Sep 28th, 2026 2:30 pm
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
- Sep 25th, 2026 9:02 am
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
- Sep 24th, 2026 9:50 am
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
- Sep 24th, 2026 7:35 am
Vertex Posts Positive Phase II Data on Kidney Disease Drug
- Sep 23rd, 2026 10:08 am
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
- Sep 23rd, 2026 9:00 am
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
- Sep 22nd, 2026 10:17 am
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
- Sep 22nd, 2026 9:00 am
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
- Sep 21st, 2026 11:29 am
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
- Sep 21st, 2026 8:59 am
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
- Sep 18th, 2026 10:09 am
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
- Sep 18th, 2026 9:09 am
Scroll